Compare Stocks: NMRA, CRON, ANRO, and ARDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$34.21 -0.1%	$27.10	$3.41 ▼ $35.41	$1.34B	1.06	374,422 shs	165,053 shs
ARDX Ardelyx	$3.91 +0.3%	$5.08	$3.86 ▼ $8.40	$974.33M	0.7	4.29 million shs	1.71 million shs
CRON Cronos Group	$3.29 +2.2%	$2.85	$2.28 ▼ $3.43	$1.22B	0.9	1.33 million shs	639,383 shs
NMRA Neumora Therapeutics	$1.64 +8.3%	$1.60	$0.83 ▼ $3.65	$308.15M	2.75	1.72 million shs	358,755 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-2.09%	+4.55%	+27.26%	+61.27%	+895.06%
ARDX Ardelyx	-3.23%	-0.26%	-23.38%	-36.17%	-34.89%
CRON Cronos Group	-2.13%	+1.90%	+15.00%	+17.52%	+33.06%
NMRA Neumora Therapeutics	-7.62%	-12.43%	-6.19%	-18.11%	-5.90%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$34.21 -0.1%	$27.10	$3.41 ▼ $35.41	$1.34B	1.06	374,422 shs	165,053 shs
ARDX Ardelyx	$3.91 +0.3%	$5.08	$3.86 ▼ $8.40	$974.33M	0.7	4.29 million shs	1.71 million shs
CRON Cronos Group	$3.29 +2.2%	$2.85	$2.28 ▼ $3.43	$1.22B	0.9	1.33 million shs	639,383 shs
NMRA Neumora Therapeutics	$1.64 +8.3%	$1.60	$0.83 ▼ $3.65	$308.15M	2.75	1.72 million shs	358,755 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-2.09%	+4.55%	+27.26%	+61.27%	+895.06%
ARDX Ardelyx	-3.23%	-0.26%	-23.38%	-36.17%	-34.89%
CRON Cronos Group	-2.13%	+1.90%	+15.00%	+17.52%	+33.06%
NMRA Neumora Therapeutics	-7.62%	-12.43%	-6.19%	-18.11%	-5.90%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.55	Moderate Buy	$37.25	8.89% Upside
ARDX Ardelyx	2.75	Moderate Buy	$13.90	255.50% Upside
CRON Cronos Group	2.40	Hold	$2.30	-30.09% Downside
NMRA Neumora Therapeutics	2.60	Moderate Buy	$6.57	300.70% Upside

Current Analyst Ratings Breakdown

Latest NMRA, CRON, ANRO, and ARDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	ARDX Ardelyx	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$9.00
8/17/2026	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00
8/17/2026	ARDX Ardelyx	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$16.00 ➝ $15.00
8/14/2026	NMRA Neumora Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$24.00 ➝ $26.00
8/13/2026	ANRO Alto Neuroscience	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $37.00
8/12/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)
8/10/2026	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$14.00 ➝ $11.00
8/7/2026	ARDX Ardelyx	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$13.00 ➝ $10.00
8/7/2026	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00
8/7/2026	ARDX Ardelyx	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$17.00 ➝ $14.00

(Data available from 8/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$5.59 per share	N/A
ARDX Ardelyx	$407.32M	2.39	N/A	N/A	$0.60 per share	6.52
CRON Cronos Group	$179.09M	6.81	$0.01 per share	262.42	$3.01 per share	1.09
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	$0.24 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$63.24M	-$2.42	N/A	N/A	N/A	N/A	-46.46%	-39.09%	N/A
ARDX Ardelyx	-$61.60M	-$0.22	N/A	16.29	N/A	-12.35%	-36.00%	-10.77%	10/29/2026 (Estimated)
CRON Cronos Group	-$9.45M	$0.20	16.45	N/A	N/A	39.08%	4.85%	4.62%	11/5/2026 (Estimated)
NMRA Neumora Therapeutics	-$236.93M	-$1.23	N/A	N/A	N/A	N/A	-242.28%	-131.32%	11/5/2026 (Estimated)

Latest NMRA, CRON, ANRO, and ARDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	NMRA Neumora Therapeutics	-$0.2401	-$0.23	+$0.0101	-$0.23	N/A	N/A
8/12/2026	Q2 2026	ANRO Alto Neuroscience	-$0.7345	-$0.65	+$0.0845	-$0.65	N/A	N/A
8/6/2026	Q2 2026	ARDX Ardelyx	-$0.05	-$0.07	-$0.02	-$0.07	$121.04 million	$120.88 million
8/6/2026	Q2 2026	CRON Cronos Group	$0.01	$0.09	+$0.08	$0.09	$44.20 million	$53.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
NMRA Neumora Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.07	14.85	14.85
ARDX Ardelyx	1.69	3.34	3.15
CRON Cronos Group	N/A	16.18	15.25
NMRA Neumora Therapeutics	1.19	4.50	5.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
ARDX Ardelyx	58.92%
CRON Cronos Group	8.71%
NMRA Neumora Therapeutics	47.65%

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.25%
ARDX Ardelyx	5.30%
CRON Cronos Group	7.80%
NMRA Neumora Therapeutics	26.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	39.24 million	34.83 million	N/A
ARDX Ardelyx	90	249.19 million	235.98 million	Optionable
CRON Cronos Group	450	370.73 million	341.81 million	Optionable
NMRA Neumora Therapeutics	108	187.90 million	137.28 million	Optionable

NMRA, CRON, ANRO, and ARDX Headlines

Recent News About These Companies

HC Wainwright Analysts Raise Earnings Estimates for NMRA

August 21 at 2:03 AM | americanbankingnews.com

Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 31,000 Shares

August 19 at 9:11 PM | marketbeat.com

Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 34,987 Shares

August 19 at 9:11 PM | marketbeat.com

Insider Selling: Neumora Therapeutics (NASDAQ:NMRA) Insider Sells 91,690 Shares

August 19 at 9:10 PM | marketbeat.com

Q3 EPS Estimate for Neumora Therapeutics Lifted by Analyst

August 19 at 8:11 AM | marketbeat.com

1,849,445 Shares in Neumora Therapeutics, Inc. $NMRA Purchased by Johnson & Johnson

August 16, 2026 | marketbeat.com

Neumora Therapeutics (NASDAQ:NMRA) Upgraded at Wall Street Zen

August 15, 2026 | marketbeat.com

Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Beats Estimates By $0.01 EPS

August 14, 2026 | marketbeat.com

Neumora Therapeutics Announces CEO Transition and Q2 Results

August 14, 2026 | tipranks.com

Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 14, 2026 | globenewswire.com

Perceptive Advisors LLC Takes $9.95 Million Position in Neumora Therapeutics, Inc. $NMRA

August 2, 2026 | marketbeat.com

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 31, 2026 | marketbeat.com

Neumora Therapeutics (NMRA) Expected to Release Earnings on Wednesday

July 29, 2026 | marketbeat.com

Neumora Therapeutics Shares Rise on Positive Obesity Drug Results

July 28, 2026 | marketwatch.com

Neumora advances NMRA-215 with positive toxicology results

July 27, 2026 | tipranks.com

Neumora Therapeutics Reports Favorable Repeat Toxicology Results for NMRA-215 and Plans IND Submission in Q4 2026

July 27, 2026 | quiverquant.comQ

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

July 27, 2026 | globenewswire.com

Neumora Therapeutics (NASDAQ:NMRA) Rating Lowered to Strong Sell at Wall Street Zen

July 25, 2026 | marketbeat.com

Siren L.L.C. Buys 2,209,039 Shares of Neumora Therapeutics, Inc. $NMRA

July 24, 2026 | marketbeat.com

Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation

July 11, 2026 | finance.yahoo.com

Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy

July 7, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NMRA, CRON, ANRO, and ARDX Company Descriptions

Alto Neuroscience NYSE:ANRO

$34.21 -0.04 (-0.12%)

As of 03:16 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Ardelyx NASDAQ:ARDX

$3.91 +0.01 (+0.26%)

As of 03:15 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Cronos Group NASDAQ:CRON

$3.29 +0.07 (+2.17%)

As of 03:16 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Neumora Therapeutics NASDAQ:NMRA

$1.64 +0.13 (+8.25%)

As of 03:16 PM Eastern

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NMRA, CRON, ANRO, and ARDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NMRA, CRON, ANRO, and ARDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NMRA, CRON, ANRO, and ARDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NMRA, CRON, ANRO, and ARDX Company Descriptions

Alto Neuroscience NYSE:ANRO

Ardelyx NASDAQ:ARDX

Cronos Group NASDAQ:CRON

Neumora Therapeutics NASDAQ:NMRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NMRA, CRON, ANRO, and ARDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NMRA, CRON, ANRO, and ARDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NMRA, CRON, ANRO, and ARDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NMRA, CRON, ANRO, and ARDX Company Descriptions

Alto Neuroscience NYSE:ANRO

Ardelyx NASDAQ:ARDX

Cronos Group NASDAQ:CRON

Neumora Therapeutics NASDAQ:NMRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools